Tom Powles/X
Mar 31, 2025, 18:51
Insights from GUtrends25 on Urothelial Cancer Treatment by Tom Powles
Tom Powles, Professor at the University of London, shared a post on X:
“At GUtrends25 we compared EV, SG, Erda(FGFR +ves), taxane +/- ramucirumab (VEGFR mAB) in pretreated urothelial cancer. The control arms performed similarly. EV & Erda (FGFR+) look quite similar, but SG slightly less activity & tox. Ram got PFS but no OS, halting VEGF in UC.
This is a suboptimal place to test drugs due to resistance/tox/ OS. Some good drugs may have been lost (potentially such as SG or RAM). Future studies will have different patient characteristics due to prior EVP. Activity post EVP is not necessarily the same so we start again.”
More posts featuring Tom Powles.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 17:58
May 29, 2025, 17:45
May 29, 2025, 17:39
May 29, 2025, 17:28